8-K: Bionano Reports Preliminary Q4 & FY25 Results Amidst Growth

Bionano Genomics reported preliminary Q4 and full-year 2025 financial results, highlighting OGM adoption and reimbursement progress despite a year-over-year revenue decrease.

Summary

• Total revenue for Q4 2025 is expected to be in the range of $7.8 million to $8.0 million, which is at the upper end of guidance but represents a decrease of 2% to 4% year-over-year.
• Nanochannel array flowcells sold in Q4 2025 are expected to be 7,554.
• Nine new OGM systems were installed in Q4 2025.
• Total revenue for the full year 2025 is expected to be in the range of $28.4 million to $28.6 million, within annual guidance but representing a decrease of 7% to 8% year-over-year.
• Nanochannel array flowcells sold in the full year 2025 are expected to be 30,171.
• Thirty-two new OGM systems were installed in full year 2025, resulting in an installed base of 387 OGM systems at year-end 2025, up from 371 at year-end 2024.
• Cash, cash equivalents, available-for-sale securities, and restricted short-term investments were approximately $29.6 million as of December 31, 2025, with $10.3 million subject to certain restrictions.
• The company transformed its business model to focus on routine users of optical genome mapping (OGM) solutions, improved its financial profile with reduced cash burn and improved gross margins.
• Significant reimbursement progress was made with the establishment of a second Category I CPT code for OGM in constitutional genetic disorders and a 47% increase in payment determination for the existing Category I CPT code for OGM use in hematologic malignancies.
• There was a significant expansion in published clinical research evidence supporting OGM as an alternative to traditional cytogenetic methods.
• A major upgrade to software and compute platforms was launched, among other product improvements.

Sentiment

Score: 5

Explanation: While Bionano met its revenue guidance and showed operational progress in OGM adoption and reimbursement, the year-over-year revenue decline and explicit 'going concern' warning due to the need for significant additional financing temper the positive developments.

Positives

• Q4 2025 revenue is expected to be at the upper end of the company's guidance range ($7.8 million to $8.0 million).
• The company improved its financial profile with reduced cash burn and improved gross margins in 2025.
• A second Category I CPT code for OGM was established for constitutional genetic disorders, expanding reimbursement opportunities.
• Payment determination for the Category I CPT code for OGM use in hematologic malignancies increased by 47%.
• The body of published clinical research evidence supporting OGM as an alternative to traditional cytogenetic methods significantly expanded.
• The installed base of OGM systems grew to 387 at year-end 2025, up from 371 at year-end 2024.
• A major upgrade to software and compute platforms was launched, enhancing product offerings.

Negatives

• Total revenue for Q4 2025 is expected to decrease by 2% to 4% year-over-year.
• Total revenue for the full year 2025 is expected to decrease by 7% to 8% year-over-year.
• The company's cash, cash equivalents, available-for-sale securities, and restricted short-term investments were approximately $29.6 million as of December 31, 2025, with $10.3 million of this amount subject to restrictions.
• The preliminary financial results are unaudited and subject to change, with a warning not to place undue reliance on them.
• The company's ability to continue as a going concern within 12 months of filing its Annual Report on Form 10-K for the year ended December 31, 2025, is dependent on managing costs and obtaining significant additional financing.

Risks

• Adjustments to preliminary financial performance measures may occur during the completion of end-of-period review and reporting processes.
• The ability to improve margins, extend cash runway, and reach a potential pathway to profitability is uncertain.
• The company's ability to continue as a going concern within 12 months of filing its Annual Report on Form 10-K for the year ended December 31, 2025, requires managing costs and obtaining significant additional financing.
• Uncertainty exists regarding the ability to execute on strategy and achieve objectives.
• The impact and utility of cost savings initiatives and recent financing are not guaranteed.
• The ability to continue driving OGM adoption by potential customers for routine use in genomic analysis is a risk.
• The impact, or lack thereof, of Category I CPT codes to accelerate or increase the adoption of OGM is uncertain.
• Continued research, presentations, and publications involving OGM and its utility compared to traditional cytogenetics and the company's technologies are not guaranteed.
• The impact of the Stratys system and VIA software to increase throughput and simplify analysis of OGM data is a risk.
• The ability to drive adoption of OGM and technology solutions is uncertain.
• The ability to further deploy new products and applications for technology platforms is a risk.
• The ability to consummate any strategic alternatives, including the risk of seeking relief under applicable insolvency laws if additional financing is not obtained, is a concern.
• The size and growth potential of the markets for products, and the ability to serve those markets, are uncertain.
• The rate and degree of market acceptance of products are risks.
• The ability to manage the growth of the business and integrate acquired businesses is a challenge.
• The ability to expand the commercial organization to address effectively existing and new markets is a risk.
• The impact from future regulatory, judicial, and legislative changes or developments in the U.S. and foreign countries is uncertain.
• The ability to compete effectively in a competitive industry is a risk.
• The introduction of competitive technologies or improvements in existing technologies and the success of any such technologies pose a threat.
• The performance of third-party contract sales organizations, suppliers, and manufacturers is a risk.
• The ability to attract and retain key scientific or management personnel is uncertain.
• The accuracy of estimates regarding expenses, future revenues, reimbursement rates, capital requirements, and needs for additional financing is a risk.
• The impact of adverse geopolitical and macroeconomic developments (e.g., bank failures, conflicts, pandemics, inflation, supply chain issues) on the business and operations is a risk.
• The ability to realize the anticipated benefits and synergies of prior and any future acquisitions or other strategic transactions is uncertain.
• The ability to attract collaborators and strategic partnerships is a risk.
• General business and financial condition risks, including those described in SEC filings, are present.

Future Outlook

The company is entering 2026 with a strong foundation and pipeline of demand, driven by its transformed business model focusing on routine OGM users, improved financial profile, expanded OGM adoption, and significant reimbursement progress. They expect continued growth in published clinical research evidence and further deployment of new products and applications. However, the ability to continue as a going concern is dependent on managing costs and obtaining significant additional financing.

Management Comments

• "2025 was a pivotal year for Bionano. We transformed our business model to focus on routine users of our optical genome mapping (OGM) solutions, improved our financial profile with reduced cash burn and improved gross margins, and expanded the use and adoption of OGM both in the U.S. and internationally."
• "We saw important reimbursement progress with the establishment of a second category I CPT code for OGM, this time in constitutional genetic disorders and a 47% increase in payment determination for the category I CPT code for OGM use in hematologic malignancies."
• "We also saw significant expansion in the body of published clinical research evidence in support of using OGM as an alternative to traditional cytogenetic methods, with continued growth both in peer-reviewed publications and reported clinical research genomes."
• "Our teams launched a major upgrade to our software and compute platforms, among other product improvements. As a result, we are entering 2026 with a strong foundation and pipeline of demand."

Industry Context

Bionano's focus on optical genome mapping (OGM) for routine use and its progress in securing Category I CPT codes for both constitutional genetic disorders and hematologic malignancies position it within the growing field of advanced genomic diagnostics. The expansion of published clinical research evidence for OGM as an alternative to traditional cytogenetic methods indicates a broader industry trend towards more comprehensive and efficient genomic analysis tools. The company's efforts to reduce cash burn and improve gross margins are critical in the capital-intensive biotechnology sector, especially for companies developing novel diagnostic platforms.

Stakeholder Impact

• Shareholders face potential dilution if additional financing is raised and a risk of insolvency if financing is not secured. There is also potential for long-term value creation if OGM adoption and profitability are achieved.
• Employees will continue to focus on operational execution and product development.
• Customers and researchers will benefit from expanded OGM adoption, improved software, and increased clinical evidence.
• Creditors face risk associated with the company's 'going concern' warning and need for additional financing.

Next Steps

• Complete customary year-end close and review procedures for Q4 and full year 2025 financial statements.
• Independent registered public accountants will review and may identify items causing final reported results to differ materially from preliminary estimates.
• Continue driving OGM adoption by potential customers for routine use.
• Further deploy new products and applications for technology platforms.
• Manage costs and obtain significant additional financing to fund strategic plans and commercialization efforts.

Key Dates

Recommendation

While Bionano shows promising operational progress in OGM adoption, reimbursement, and product development, the significant year-over-year revenue decline and the explicit 'going concern' warning due to the need for substantial additional financing introduce considerable financial risk. The preliminary nature of the results also adds uncertainty. Investors should hold, awaiting the audited financial statements and clearer plans for addressing the financing needs and achieving profitability before making further investment decisions.

Keywords

Bionano Genomics, BNGO, Optical Genome Mapping, OGM, Preliminary Financial Results, Q4 2025, Full Year 2025, Revenue, Flowcells, Installed Systems, Cash, CPT Code, Constitutional Genetic Disorders, Hematologic Malignancies, Genome Analysis, Diagnostics, Biotechnology, Life Sciences